The metabolic syndrome, also known as syndrome X, is characterizedby abdominal obesity, atherogenic dyslipidemia, hypertension,insulin resistance, inflammation, and prothrombotic states.1Diagnostic of the metabolic syndrome are abnormalities in threeor more of the clinical criteria of the Adult Treatment PanelIII of the National Cholesterol Education Program, which includethe following: a waist circumference of more than 102 cm inmen and more than 88 cm in women; a triglyceride level of 150mg per deciliter or more; a level of high-density lipoprotein(HDL) cholesterol of less than 40 mg per deciliter in men andless than 50 . . . [Full Text of this Article]
Reverse Endocrinology of RXR Heterodimers
RXRs: Partners in Signaling
PPARs: Fatty-Acid Sensors
PPAR
PPAR
PPAR
LXRs: Sterol Sensors
FXR: Bile Acid Sensor
Thyroid Hormone Receptors
Perspectives
Source Information
From the Howard Hughes Medical Institute, Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas.
Address reprint requests to Dr. Mangelsdorf at the University of Texas Southwestern Medical Center, 6001 Forest Park Rd., Dallas, TX 75390, or at davo.mango@utsouthwestern.edu.
Mansouri, R. M., Bauge, E., Staels, B., Gervois, P.
(2008). Systemic and Distal Repercussions of Liver-Specific Peroxisome Proliferator-Activated Receptor-{alpha} Control of the Acute-Phase Response. Endocrinology
149: 3215-3223
[Abstract][Full Text]
Kamei, Y., Miura, S., Suganami, T., Akaike, F., Kanai, S., Sugita, S., Katsumata, A., Aburatani, H., Unterman, T. G., Ezaki, O., Ogawa, Y.
(2008). Regulation of SREBP1c Gene Expression in Skeletal Muscle: Role of Retinoid X Receptor/Liver X Receptor and Forkhead-O1 Transcription Factor. Endocrinology
149: 2293-2305
[Abstract][Full Text]
Berkenstam, A., Kristensen, J., Mellstrom, K., Carlsson, B., Malm, J., Rehnmark, S., Garg, N., Andersson, C. M., Rudling, M., Sjoberg, F., Angelin, B., Baxter, J. D.
(2008). From the Cover: The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl. Acad. Sci. USA
105: 663-667
[Abstract][Full Text]
Commerford, S. R., Vargas, L., Dorfman, S. E., Mitro, N., Rocheford, E. C., Mak, P. A., Li, X., Kennedy, P., Mullarkey, T. L., Saez, E.
(2007). Dissection of the Insulin-Sensitizing Effect of Liver X Receptor Ligands. Mol. Endocrinol.
21: 3002-3012
[Abstract][Full Text]
Hessel, S., Eichinger, A., Isken, A., Amengual, J., Hunzelmann, S., Hoeller, U., Elste, V., Hunziker, W., Goralczyk, R., Oberhauser, V., von Lintig, J., Wyss, A.
(2007). CMO1 Deficiency Abolishes Vitamin A Production from beta-Carotene and Alters Lipid Metabolism in Mice. J. Biol. Chem.
282: 33553-33561
[Abstract][Full Text]
Kotokorpi, P., Ellis, E., Parini, P., Nilsson, L.-M., Strom, S., Steffensen, K. R., Gustafsson, J.-A., Mode, A.
(2007). Physiological Differences between Human and Rat Primary Hepatocytes in Response to Liver X Receptor Activation by 3-[3-[N-(2-Chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino]propyloxy]phenylacetic Acid Hydrochloride (GW3965). Mol. Pharmacol.
72: 947-955
[Abstract][Full Text]
Nilsson, M., Dahlman-Wright, K., Karelmo, C., Gustafsson, J.-A., Steffensen, K. R.
(2007). Elk1 and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRB gene promoter. Nucleic Acids Res
0: gkm492v1-11
[Abstract][Full Text]
Smit, J. W. A., Stokkel, M. P. M., Pereira, A. M., Romijn, J. A., Visser, T. J.
(2007). Bexarotene-Induced Hypothyroidism: Bexarotene Stimulates the Peripheral Metabolism of Thyroid Hormones. J. Clin. Endocrinol. Metab.
92: 2496-2499
[Abstract][Full Text]
Debevec, D., Christian, M., Morganstein, D., Seth, A., Herzog, B., Parker, M., White, R.
(2007). Receptor Interacting Protein 140 Regulates Expression of Uncoupling Protein 1 in Adipocytes through Specific Peroxisome Proliferator Activated Receptor Isoforms and Estrogen-Related Receptor {alpha}. Mol. Endocrinol.
21: 1581-1592
[Abstract][Full Text]
Woods, C. G., Vanden Heuvel, J. P., Rusyn, I.
(2007). Genomic Profiling in Nuclear Receptor-Mediated Toxicity. Toxicol Pathol
35: 474-494
[Abstract][Full Text]
Houten, S. M., Volle, D. H., Cummins, C. L., Mangelsdorf, D. J., Auwerx, J.
(2007). In Vivo Imaging of Farnesoid X Receptor Activity Reveals the Ileum as the Primary Bile Acid Signaling Tissue. Mol. Endocrinol.
21: 1312-1323
[Abstract][Full Text]
Dubrac, S., Stoitzner, P., Pirkebner, D., Elentner, A., Schoonjans, K., Auwerx, J., Saeland, S., Hengster, P., Fritsch, P., Romani, N., Schmuth, M.
(2007). Peroxisome Proliferator-Activated Receptor-{alpha} Activation Inhibits Langerhans Cell Function. J. Immunol.
178: 4362-4372
[Abstract][Full Text]
Nohara, A., Kawashiri, M.-a., Claudel, T., Mizuno, M., Tsuchida, M., Takata, M., Katsuda, S., Miwa, K., Inazu, A., Kuipers, F., Kobayashi, J., Koizumi, J., Yamagishi, M., Mabuchi, H.
(2007). High Frequency of a Retinoid X Receptor {gamma} Gene Variant in Familial Combined Hyperlipidemia That Associates With Atherogenic Dyslipidemia. Arterioscler. Thromb. Vasc. Bio.
27: 923-928
[Abstract][Full Text]
Rodrigue-Way, A., Demers, A., Ong, H., Tremblay, A.
(2007). A Growth Hormone-Releasing Peptide Promotes Mitochondrial Biogenesis and a Fat Burning-Like Phenotype through Scavenger Receptor CD36 in White Adipocytes. Endocrinology
148: 1009-1018
[Abstract][Full Text]
Beyea, M. M., Heslop, C. L., Sawyez, C. G., Edwards, J. Y., Markle, J. G., Hegele, R. A., Huff, M. W.
(2007). Selective Up-regulation of LXR-regulated Genes ABCA1, ABCG1, and APOE in Macrophages through Increased Endogenous Synthesis of 24(S),25-Epoxycholesterol. J. Biol. Chem.
282: 5207-5216
[Abstract][Full Text]
Tuohimaa, P., Tenkanen, L., Syvala, H., Lumme, S., Hakulinen, T., Dillner, J., Hakama, M.
(2007). Interaction of Factors Related to the Metabolic Syndrome and Vitamin D on Risk of Prostate Cancer. Cancer Epidemiol. Biomarkers Prev.
16: 302-307
[Abstract][Full Text]
Brown, J. D., Plutzky, J.
(2007). Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets. Circulation
115: 518-533
[Abstract][Full Text]
Ziouzenkova, O., Orasanu, G., Sukhova, G., Lau, E., Berger, J. P., Tang, G., Krinsky, N. I., Dolnikowski, G. G., Plutzky, J.
(2007). Asymmetric Cleavage of {beta}-Carotene Yields a Transcriptional Repressor of Retinoid X Receptor and Peroxisome Proliferator-Activated Receptor Responses. Mol. Endocrinol.
21: 77-88
[Abstract][Full Text]
Nilsson, M., Stulnig, T. M., Lin, C.-Y., Yeo, A. L., Nowotny, P., Liu, E. T., Steffensen, K. R.
(2007). Liver X Receptors Regulate Adrenal Steroidogenesis and Hypothalamic-Pituitary-Adrenal Feedback. Mol. Endocrinol.
21: 126-137
[Abstract][Full Text]
Hu, T., Chouinard, M., Cox, A. L., Sipes, P., Marcelo, M., Ficorilli, J., Li, S., Gao, H., Ryan, T. P., Michael, M. D., Michael, L. F.
(2006). Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation. J. Biol. Chem.
281: 39831-39838
[Abstract][Full Text]
Moore, D. D., Kato, S., Xie, W., Mangelsdorf, D. J., Schmidt, D. R., Xiao, R., Kliewer, S. A.
(2006). International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor {alpha}, Farnesoid X Receptor beta, Liver X Receptor {alpha}, Liver X Receptor beta, and Vitamin D Receptor. Pharmacol. Rev.
58: 742-759
[Abstract][Full Text]
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., Gronemeyer, H.
(2006). International Union of Pharmacology. LXIII. Retinoid X Receptors. Pharmacol. Rev.
58: 760-772
[Abstract][Full Text]
Liby, K., Rendi, M., Suh, N., Royce, D. B., Risingsong, R., Williams, C. R., Lamph, W., Labrie, F., Krajewski, S., Xu, X., Kim, H., Brown, P., Sporn, M. B.
(2006). The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor-Negative Model of Breast Cancer.. Clin. Cancer Res.
12: 5902-5909
[Abstract][Full Text]
Svegliati-Baroni, G., Candelaresi, C., Saccomanno, S., Ferretti, G., Bachetti, T., Marzioni, M., De Minicis, S., Nobili, L., Salzano, R., Omenetti, A., Pacetti, D., Sigmund, S., Benedetti, A., Casini, A.
(2006). A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats: Role of Peroxisome Proliferator-Activated Receptor-{alpha} and n-3 Polyunsaturated Fatty Acid Treatment on Liver Injury. Am. J. Pathol.
169: 846-860
[Abstract][Full Text]
Marra, F
(2006). Thiazolidinediones and hepatic fibrosis: don't wait too long. Gut
55: 917-919
[Full Text]
Okada, T., Wada, J., Hida, K., Eguchi, J., Hashimoto, I., Baba, M., Yasuhara, A., Shikata, K., Makino, H.
(2006). Thiazolidinediones Ameliorate Diabetic Nephropathy via Cell Cycle-Dependent Mechanisms. Diabetes
55: 1666-1677
[Abstract][Full Text]
Freemantle, S. J., Dragnev, K. H., Dmitrovsky, E.
(2006). The retinoic Acid paradox in cancer chemoprevention.. JNCI J Natl Cancer Inst
98: 426-427
[Full Text]
Persson, P. B.
(2006). From clinical insights to new therapies. Am. J. Physiol. Regul. Integr. Comp. Physiol.
290: R124-R125
[Full Text]
Hegele, R. A.
(2005). Retinoid X Receptor Heterodimers in the Metabolic Syndrome.. NEJM
353: 2088-2088
[Full Text]
Previous
